Lung Cancer Considered host Dr. Narjust Florez leads an informed discussion on the AEGEAN Trial, which explored neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resected NSCLC.

Podcast Host:

• Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, USA 

Podcast Guests: 

• Tercia Reis, MD, Thoracic Medical Oncologist, Grupo Oncoclinicas in Salvador, Brazil